News | Proton Therapy | July 01, 2022

The ConformalFLASH Alliance will be the first collaboration platform between academia and industry to bring ConformalFLASH proton therapy to the clinic 

The ConformalFLASH Alliance will be the first collaboration platform between academia and industry to bring ConformalFLASH proton therapy to the clinic

July 1, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today the launch of the ConformalFLASH[1] Alliance, which aims to accelerate the delivery of ConformalFLASH Proton Therapy to patients.
ConformalFLASH is a novel delivery technique combining ultra-high dose rate FLASH radiotherapy with the unique Bragg Peak properties of protons. These ultra-high dose rates create the opportunity to optimize and accelerate the radiotherapy process and increase the therapeutic ratio.[2]
The ConformalFLASH Alliance brings together academic and industry expertise to foster a joint understanding of the fundamentals of FLASH Therapy and how to combine it with the unique properties of the Proton Bragg Peak. The objective is to enable the delivery of treatments with reduced side effects to patients and increased patient comfort through a reduced treatment course.
Swati Girdhani, Director of Research Collaborations at IBA, said: “In the last few years IBA has been working closely with its customers, leading researchers in FLASH Radiotherapy, and industry partners such as IBA Dosimetry and RaySearch to develop ConformalFLASH and to gain a better understanding of how it could be used in the clinic. With the ConformalFLASH Alliance, we have created a space to share ideas, deepen insights and ultimately accelerate the translation of this technology into the clinic.”

Prof. James M. Metz, MD, Henry K. Pancoast Professor of Radiation Oncology at the University of Pennsylvania, said “Building on our research of FLASH Proton Therapy, we look forward to deepening our national and international collaborations and advancing knowledge of this technology as a potential treatment option.”
Prof. Dr. Stefan Both, Head of Medical Physics at UMC Groningen, said: “In March 2022, we announced a partnership with IBA to leverage the combined strength of the Particle Therapy Research Center (PARTREC) and Groningen Proton Therapy Center (GPTC) to embark on this long-term collaboration with IBA to study FLASH Therapy for breast cancer. With the ConformalFLASH Alliance, we can go one step further in collaborating with other major academic centers across the world, and hope to accelerate the translation of FLASH to the clinic.”
Erik Traneus, Head of Sales Particle Therapy and Senior Researcher at Raysearch added: “We are delighted to support the development of ConformalFLASH treatment modality and participate to the launch of the ConformalFLASH Alliance. RayStation today can be equipped with specific research modules that will help answer the big research questions that the Alliance will be addressing.” 

For more information: www.iba-worldwide.com 

References: 

1] ConformalFLASH is a registered brand of IBA’s Proton FLASH irradiation solution currently under research and development phase.
[2] J. Bourhis, P. Montay-Gruel, P. Gonçalves Jorge et al., Clinical translation of FLASH Radiotherapy: Why and how?, Radiotherapy and Oncology 


Related Content

News | Radiopharmaceuticals and Tracers

September 27, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time September 27, 2023
arrow
News | Radiation Therapy

September 27, 2023 — The American Society for Radiation Oncology (ASTRO) announced the three winning research proposals ...

Time September 27, 2023
arrow
News | Breast Imaging

September 27, 2023 — Researchers at Weill Cornell Medicine have discovered that radiation therapy combined with two ...

Time September 27, 2023
arrow
Feature | ASTRO | By Christine Book

September 26, 2023 — Ahead of the 65th American Society for Radiation Oncology Annual Meeting, ASTRO 2023, ITN’s ...

Time September 26, 2023
arrow
News | Prostate Cancer

September 22, 2023 — According to an accepted manuscript published in the American Journal of Roentgenology (AJR) ...

Time September 22, 2023
arrow
Feature | Radiation Oncology

The radiation oncology community lost a leader this past summer, with the passing of Jay Loeffler, MD, FACR, FASTRO. He ...

Time September 21, 2023
arrow
Feature | Proton Therapy | By Christine Book

An overview of significant developments in proton therapy, over just the past six months, reinforces the pace of ...

Time September 21, 2023
arrow
News | Radiation Therapy

September 20, 2023 — RefleXion Medical, Inc., a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a ...

Time September 20, 2023
arrow
News | SNMMI

September 18, 2023 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI), as a professional society ...

Time September 18, 2023
arrow
News | PET-CT

September 8, 2023 — Positron Corporation, a leading molecular imaging medical device company, is pleased to announce ...

Time September 08, 2023
arrow
Subscribe Now